CLDX Celldex Therapeutics

Celldex to Present at Upcoming Investor Conferences

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:

  • Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ET
  • TD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET
  • 8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET

Live webcasts of the presentations will be available on the "" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.

Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
07/11/2025

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Announces Proposed Public Offering of Common Stock

Celldex Announces Proposed Public Offering of Common Stock HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other con...

42m 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urtica...

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab i...

March 27, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment...

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented new positive data from the Phase 2 ColdU a...

March 1, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontan...

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celld...

February 27, 2026 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and...

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 Phase 1 CDX-622 Proof of Mechanism study in asthma initiatedCompany prepares...

February 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch